RECEIVED CENTRAL FAX CENTER

APK 2 7 2005

FAX TRANSMISSION

DATE:

April 27, 2005

PTO IDENTIFIER:

Application Number 09/904,756

Patent Number

6,750,199

William V. Curran

MESSAGE TO:

US Patent and Trademark Office

FAX NUMBER:

(703) 872-9306

FROM:

DARBY & DARBY P.C.

Jeffrey C. Pepe

PHONE:

(206) 262-8900

Attorney Dkt. #:

20343/1202369-US3

PAGES (Including Cover Sheet): 11

CONTENTS: Certificate of Transmission (1 page)

Revocation of Power of Attorney or Authorization of Agent (1 page)

Statement under 37 CFR 3.73(b) (1 page)

Copy of Assignments (7 pages)

If your receipt of this transmission is in error, please notify this firm immediately by collect call to sender at (206) 262-8900 and send the original transmission to us by return mail at the address below.

This transmission is intended for the sole use of the individual and entity to whom it is addressed, and may contain information that is privileged, confidential and exempt from disclosure under applicable law. You are hereby notified that any dissemination, distribution or duplication of this transmission by someone other than the intended addressee or its designated agent is strictly prohibited.

DARBY & DARBY P.C.

P.O. Box 5257, New York, New York 10150-5257 Telephone: (212) 527-7700 Facsimile: (212) 527-7701 PTO/SB/97 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031

U. S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of Information unless it displays a valid OMB control number. Application No. (if known): 09/904,758 Attorney Docket No.: 20343/1202369-US3 Certificate of Transmission under 37 CFR 1.8 I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office. April 27, 2005 Signature Linda Povinelli Typed or printed name of person signing Certificate Each paper must have its own certificate of transmission, or this certificate must Note: identify each submitted paper. Revocation of Power of Attorney or Authorization of Agent (1 page) Statement under 37 CFR 3.73(b) (1 page) Copy of Assignments (7 pages)

Under the	e Paperwork Reduction Act of 1895, no persons	are required to	IIC Datast and To	adamadı Affici		PTO/SB/82 (09-04) gh 11/30/2005. OMB 0851-0038 DEPARTMENT OF COMMERCE splays a valid OMB control number		
REVOCATION OF POWER OF			Patent Number		6,750,199			
		Issue	Date	June 15,	June 15, 2004			
NE	ATTORNEY WITH NEW POWER OF ATTORNEY		lamed Inventor	William \	William V. Curran			
AND CHANGE OF CORRESPONDENCE ADDRESS		SS Art Ur	út					
ł	SINGLO OF CONTINUES ADDRESS		ner Name					
		Attorn	ey Docket Number	20343/1202369-US3 (424C1)				
I hereby rev	I hereby revoke all previous powers of attorney given in the above-identified application.							
A Po	ower of Attorney is submitted herev	vith.			•			
OR	•							
X I here	eby appoint the practitioners assoc	ciated with	the Customer Nur	nber:	0	7278		
[]] -:								
X Pleas	se change the correspondence add	dress for th	e above-identified	l application	to:			
x The address associated with Clustomer Number 07278								
OR Customer Number: 07278								
Firm or Individual Name DARBY & DARBY P.C.								
Address						-		
City	<u> </u>							
Country		State			Zip			
Telephone			F	ax				
am the	:							
Applic	cant/Inventor.							
Assignee of record of the entire interest. See 37 CFR 3.71. Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96)								
SIGNATURE of Applicant or Assignee of Record								
Signature Surian Conform								
Name	Name Richard Coulson, VP, Micrologix Biotech Inc.							
Date	8- Africo - 201	05	Telephon			04-221-9666		
NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below.								
*Total of1 forms are submitted.								

PTO/SB/96 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, 'no persons are required to respond to a collection of information unless it displays a valid OMB control number.

	STATEMENT UNDER 37 CFR 3.73(b)							
Applicant/Patent Owner: Willia	T							
Application No./Patent No.: 09/90								
Entitled: <u>Antimicrobial Sulfoni</u>	mide Derivative	of Lipopeptide Antible	otics					
Micrologix Biotech Inc.	_, 1	acorpoi	ration					
(Name of Assignee)		(Type of Assignee, e.g.	., corporation, partnership, mment agency, etc.)					
states that it is:			птен; аденсу, выл					
1. X the assignee of the entire righ		st; or						
2. [] an assignee of an undivided p	part interest							
in the patent application/patent iden	itified above by vir	tue of either:						
Reel, Frame, or OR	A. [] An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel, Frame, or for which a copy thereof is attached.							
B. X A chain of title from the invent current assignee as shown be	tor(s), of the paten elow:	it application/patent ide	ntified above, to the					
1. From: William V. Curran et	<u>.al.</u> Tc	:Biosource Pharm, In	IC.					
The document was recorde Reel, Frame,	d in the United Sta or for which a co	ates Patent and Traden py thereof is attached	nark Office at d					
2. From: Biosource Pharm, In	<u>тс.</u> То	Intrabiotics Pharmac	ceuticals, Inc.					
The document was recorded Reel, Frame,	d in the United Sta or for which a co	ites Patent and Traden py thereof is attached	nark Office at					
 From:<u>Intrabiotics Pharmace</u> Inc. 								
The document was recorded Reel, Frame, c	d in the United Sta or for which a co	ites Patent and Tradem py thereof is attached	nark Office at I.					
Additional documents in the								
Copies of assignments or other attached.	er documents in the	e chain of title noted in	B above are					
[<u>NOTE</u> : A separate copy (<i>i.e.</i> , the original submitted to Assignment Division in accord the USPTO. <u>See</u> MPEP 302.8]	l assignment documen rdance with 37 CFR P	it or a true copy of the origina art 3, if the assignment is to	al document) must be be recorded in the records					
The undersigned (whose title is supp	olied below) is auth	orized to act on behalf	of the assignee.					
16 September 20		armes M. DeMesa, M.D	_					
		gwer m)erne	m					
		Signature	•					
		President and CEC	0					

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer U.S. Patent and Trademark Office. Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

299811 (09-14-01)

ASSIGNMENT

WHEREAS, we, William V. Curran, having the mailing address of 27 Harding Street, Pearl River, New York 10965, Richard A. Leese, having the mailing address of 7 Marget Ann Lane, Suffern, New York 10901, Howard Jarolmen, having the mailing address of 26-07 Merritt Place, Fair Lawn, New Jersey 07410 and Donald B. Borders, having the mailing address of 13 Heatherhill Lane, Suffern, New York 10901 (hereinafter referred to as ASSIGNORS), are the joint inventors of an invention entitled "ANTIMICROBIAL SULFONIMIDE DERIVATIVES OF LIPOPEPTIDE ANTIBIOTICS," as described and claimed in the specification for which an application for United States letters patent was filed on July 13, 2001 and assigned Application No. 09/904,756. This application is a continuation-in-part of U.S. Patent Application No. 09/760,328, filed January 12, 2001, which claims the benefit of Provisional Application No. 60/219,059, filed on July 17, 2000 and Provisional Application No. 60/220,950, filed July 26, 2000.

WHEREAS, BioSource Pharm, Inc. (hereinafter referred to as ASSIGNEE), a corporation of the State of New York having a place of business at 135 Route 59 East, Spring Valley, New York 10977 is desirous of acquiring the entire right, title and interest in and to the invention and in and to any letters patent that may be granted therefor in the United States and in any and all foreign countries;

NOW, THEREFORE, in exchange for good and valuable consideration, the receipt of which is hereby acknowledged, ASSIGNORS hereby sell, assign and transfer unto said ASSIGNEE the entire right, title and interest in and to said invention, said application and any and all letters patent which may be granted for said invention in the United States of America and its territorial possessions and in any and all foreign countries, and in any and all divisions, reissues and continuations thereof, including the right to file foreign applications directly in the name of ASSIGNEE and to claim priority rights deriving from said United States application to which said foreign applications are entitled by virtue of international convention, treaty or otherwise, said invention, application and all letters patent on said invention to be held and enjoyed by ASSIGNEE and its successors and assigns as fully and entirely as the same would have been held and enjoyed by ASSIGNORS had this assignment, transfer and sale not been made. ASSIGNORS hereby authorize and request the Commissioner of Patents and Trademarks to issue all letters patent on said invention to ASSIGNOE. ASSIGNORS agree to execute all instruments and documents required for the making and prosecution of applications for United

Application No. 09/904,756

States and foreign letters pat		. •	_	ing letters patent, or for the
purpose of protecting title to	said invention	or letters patent there	for.	
7/16/62		William V. Curran	V	Tuna 2
Date		William V. Curran		
State of New York County of Rock lan	<u>, </u>	SS.		
County of Koch 194	<u>d</u>)			
I certify that	I know or have	e satisfactory evidence	e tha	t William V. Curran is the
person who appeared before	me, and said	person acknowledge	d that	t he signed this instrument
and acknowledged it to be h	is free and volu	untary act for the use	s and	purposes mentioned in the
instrument.	٥			
s. Obwe	Dated	Cetuces		
CELLA C. BALLE OF NEW YORK	Signature of	· ·		
RELLA C. BAZLEN Public, State of New York 4622290 Change 1317	Notary Public	: Ostacee	C	Bozlen
Public States 4622290 A622290 Alified in Rockland Jan Scion Expires				BAZIEN
	My appointm	ent expires 10/3	1/2	002
Tuly 17, 2002		Richard A. Leese	<u>a.</u>	Lean
State of New York				
County of Rock/and		SS.		
I certify that	I know or hav	e satisfactory eviden	ce tha	at Richard A. Leese is the
person who appeared before	me, and said	person acknowledge	d that	he signed this instrument
and acknowledged it to be h	is free and volu	untary act for the use:	s and	purposes mentioned in the
instrument.		-		•
	Dated July	117 2002		
C BATIEN YOUR	Signature of		,	
STRELLA State of County 034	Notary Public	Struck	Be	lex
STRELLA C. EAZLEN Vork STRELLA C. EAZLEN YOUNIC, State of New York 1622290 16229	•	ESTRE11A		BAZ/EN_
wisziou r	My annointme	ent expires /0/3/	1200	7

660081.424C1

Application No. 09/904,756

7/17/02 Date	·	Howard Jarolmen
State of New Jec. County of Bergen)	ss.
person who appeared befor	e me, and said nis free and volume Dated Signature of Notary Public Printed Name	re satisfactory evidence that Howard Jarolmen is the person acknowledged that he signed this instrument untary act for the uses and purposes mentioned in the company of the second purposes mentioned in the second purpose mentioned in the second purpos
Date Date 17, 20 State of New York County of Rockland	72 	Donald B. Borders Ss.
person who appeared before	me, and said jis free and volu	ESTRELLA C. BAZIEN
(JCP:lmp) 298035		

COPY

Darbyfax

ASSIGNMENT

WHEREAS, BioSource Pharm, Inc. (hereinafter referred to as ASSIGNOR), a corporation of the State of New York having a place of business at 135 Route 59 East, Spring Valley, New York 10977, is the owner of record of an invention entitled "ANTIMICROBIAL SULFONIMIDE DERIVATIVES OF LIPOPEPTIDE ANTIBIOTICS," as described and claimed in the specification for which an application for United States letters patent was filed on July 13, 2001 and assigned Application No. 09/904,756. This application is a continuation-in-part of U.S. Patent Application No. 09/760,328, filed January 12, 2001, which claims the benefit of Provisional Application No. 60/219,059, filed on July 17, 2000 and Provisional Application No. 60/220,950, filed July 26, 2000; and is desirous of assigning to the Assignee its right title and interest in the invention;

WHEREAS, IntraBiotics Pharmaceuticals, Inc. (hereinafter referred to as ASSIGNEE), a corporation of the State of Delaware, having a place of business at 1245 Terra Bella Avenue, Mountain View, California 94043, is desirous of acquiring the entire right, title and interest in and to the invention and in and to any letters patent that may be granted therefore in the United States and in any and all foreign countries;

NOW, THEREFORE, in exchange for good and valuable consideration, the receipt of which is hereby acknowledged, ASSIGNOR hereby sells, assigns and transfers unto said ASSIGNEE the entire right, title and interest in and to said invention, said application and any and all letters patent which may be granted for said invention in the United States of America and its territorial possessions and in any and all foreign countries, and in any and all divisions, reissues and continuations thereof, including the right to file foreign applications directly in the name of ASSIGNEE and to claim priority rights deriving from said United States application to which said foreign applications are entitled by virtue of international convention, treaty or otherwise, said invention, application and all letters patent on said invention to be held and enjoyed by ASSIGNEE and its successors and assigns for their use and benefit and of their successors and assigns as fully and entirely as the same would have been held and enjoyed by ASSIGNOR had this assignment, transfer and sale not been made. ASSIGNOR hereby authorizes and requests that any and all letters patent on said invention be issued to ASSIGNEE. ASSIGNOR agrees to execute all instruments and documents required for the making and prosecution of applications for United States and foreign letters patent on said invention, for

660081.424C1

p.9

U.S. . at Application No. 09/904,756

litigation regarding said letters patent, or for the purpose of protecting title to said invention or letters patent therefor.

Darbyfax

		BIOSOURCE PHARM, INC.
Dete 19, 200.	<u>2</u> By	Donald B. Borders, Ph.D. Its President
State of New York)	
County of Rockland)	SS.
person who appeared before on oath stated that he was	me, and said pauthorized to em, Inc. to be the instrumed Dated Signature of Notary Public Printed Name	e satisfactory evidence that Donald B. Borders is the person acknowledged that he signed this instrument, execute the instrument, and acknowledged it as the he free and voluntary act of said corporation for the tent. 19,3003 Coccur C Bores ESTREILA C BAZIEN ent expires 10/31/2003
Commission 2.		
8-12-72 Date	By .	Ernest Mario, Ph.D. Henry Fuchs, MD Its Chairman and CEO President and COO
State of California County of Santa Clara)))	SS.
who appeared before me, and stated that he was authorized and CEO of IntraBiotics P corporation for the uses and p MARCIA L PETERSON Commission # 1257181 Notory Public - Colifornia Sonta Clora Courty My Comm Emission 14.2004	I said person and to execute the charmaceuticals urposes mention	Delia Steleson Marcia L. Peterson
(JCI ⁺ :lmp) 298072		
660081.424C1	2 (of 2



ASSIGNMENT

WHEREAS, IntraBiotics Pharmaceuticals, Inc. (hereinafter referred to as ASSIGNOR), a corporation of the State of Delaware, having a place of business at 1245 Terra Bella Avenue, Mountain View, California 94043, is the owner of record of an invention entitled "ANTIMICROBIAL SULFONIMIDE DERIVATIVES OF LIPOPEPTIDE ANTIBIOTICS," as described and claimed in the specification for which an application for United States letters patent was filed on July 13, 2001 and assigned Application No. 09/904,756. This application is a continuation-in-part of U.S. Patent Application No. 09/760,328, filed January 12, 2001, which claims the benefit of Provisional Application No. 60/219,059, filed on July 17, 2000 and Provisional Application No. 60/220,950, filed July 26, 2000; and is desirous of assigning to the Assignee its right title and interest in the invention;

WHEREAS, Micrologix Biotech Inc. (hereinafter referred to as ASSIGNEE), a corporation of the Province of British Columbia, in the country of Canada, having a place of business at 3650 Wesbrook Mall, Vancouver, British Columbia V6S 2L2, is desirous of acquiring the entire right, title and interest in and to the invention and in and to any letters patent that may be granted therefore in the United States and in any and all foreign countries;

NOW, THEREFORE, in exchange for good and valuable consideration, the receipt of which is hereby acknowledged, ASSIGNOR hereby sells, assigns and transfers unto said ASSIGNEE the entire right, title and interest in and to said invention, said application and any and all letters patent which may be granted for said invention in the United States of America and its territorial possessions and in any and all foreign countries, and in any and all divisions, reissues and continuations thereof, including the right to file foreign applications directly in the name of ASSIGNEE and to claim priority rights deriving from said United States application to which said foreign applications are entitled by virtue of international convention, treaty or otherwise, said invention, application and all letters patent on said invention to be held and enjoyed by ASSIGNEE and its successors and assigns for their use and benefit and of their successors and assigns as fully and entirely as the same would have been held and enjoyed by ASSIGNOR had this assignment, transfer and sale not been made. ASSIGNOR hereby authorizes and requests that any and all letters patent on said invention be issued to ASSIGNEE. ASSIGNOR agrees to execute all instruments and documents required for the making and prosecution of applications for United States and foreign letters patent on said invention, for

U.S. . .nt Application No. 09/904,756

litigation regarding said letters patent, or for the purpose of protecting title to said invention or letters patent therefor.

Date	8-12-02	Ву	Henry J.	Fuchs, M.D. ent and Chief	8 ~	<u>l</u>	NC.
State of C	alifornia)	SS.		·		
County of	Santa Clara	j					
on oath standard a voluntary a MARCLI Commits Notory Pt Sonto	o appeared befor ated that he was and Chief Opera	t I know or have me, and said per me, and said per sauthorized to exting Officer of I ation for the uses Dated Signature of Notary Public Printed Name My appointments	execute the execut	nowledged the instrument, s Pharmaceutoses mentioned to the control of the contro	hat he sig and ack ticals, Inc	med this inst nowledged i to be the f nstrument.	trument
Septem Date	ber 16, 2	-002 By	James M.	OGIX BIOTE LL LL LL DeMesa, M.I ent and CEO	ense		
Province of Country of	f British Columl Canada		ss.				
on oath sta President a	appeared before ted that he was nd CEO of Mi	I know or have e me, and said possible authorized to exicologix Biotect purposes mention Dated	erson ackreceute the h Inc. to ned in the	nowledged the instrument, be the free instrument.	at he sign and ackn and vol	ned this instruction owledged it untary act of the second	rument,
(JCP:lmp)	298077	Moes	VIOF	203 - 4545	WEST I	OBLIC OTH AVENT C. V6R 4N	UE 2
660081.424C1		2 o	f 2			ালন ব্র	₹.